Institute for Ethics and Emerging Technologies






The IEET is a 501(c)3 non-profit, tax-exempt organization registered in the State of Connecticut in the United States. Please give as you are able, and help support our work for a brighter future.


Search the IEET
Subscribe and Contribute to:


Technoprogressive? BioConservative? Huh?
Quick overview of biopolitical points of view




whats new at ieet

Technology Made Us Human

ETER9: The Social Network That Turns Your Personality Into an Immortal Artificial Intelligence

Would AI and Aliens be Moral in a Godless Universe?

Transhumanist Therapy IV: The Current Crisis in Psychiatry

Practopoiesis Tells Us Machine Learning Isn’t Enough

Ensuring Human Control Over Military Robotics


ieet books

The End of the Beginning: Life, Society and Economy on the Brink of the Singularity
Author
Ben Goertzel


comments

Valkyrie Ice on 'Transhumanism will be a Victorious Revolution (my modest predictions)' (Aug 28, 2015)

Laurence Hitterdale on 'Do Extraterrestials Philosophize?' (Aug 28, 2015)

Gear0Mentation on 'Transhumanism will be a Victorious Revolution (my modest predictions)' (Aug 28, 2015)

Valkyrie Ice on 'Transhumanism will be a Victorious Revolution (my modest predictions)' (Aug 27, 2015)

Gear0Mentation on 'Transhumanism will be a Victorious Revolution (my modest predictions)' (Aug 27, 2015)

Giulio Prisco on 'Network Economies: Economic System as a Configurable Parameter' (Aug 27, 2015)

rms on 'Network Economies: Economic System as a Configurable Parameter' (Aug 27, 2015)







Subscribe to IEET News Lists

Daily News Feed

Longevity Dividend List

Catastrophic Risks List

Biopolitics of Popular Culture List

Technoprogressive List

Trans-Spirit List



JET

Enframing the Flesh: Heidegger, Transhumanism, and the Body as “Standing Reserve”

Moral Enhancement and Political Realism

Intelligent Technologies and Lost Life

Hottest Articles of the Last Month


8 Craziest Mega-Engineering Projects We Could Use to Rework the Earth
Aug 13, 2015
(5783) Hits
(0) Comments

The Social Fabric of a Technically Advanced Society
Aug 1, 2015
(5512) Hits
(3) Comments

Free Will, Buddhism, and Mindfulness Meditation - interview with Terry Hyland
Aug 8, 2015
(5443) Hits
(0) Comments

Starting from Scratch: The Basic Building Blocks of AI
Aug 23, 2015
(5265) Hits
(0) Comments



IEET > Security > Life > Vision > Contributors > Simon Smith

Print Email permalink (0) Comments (3275) Hits •  subscribe Share on facebook Stumble This submit to reddit submit to digg


Marketing to Dr. Watson: Here’s how we might use data to influence machines


Simon Smith
By Simon Smith
simonsmith.ca

Posted: Apr 5, 2013

This past month, IBM’s Jeopardy-winning AI Watson furthered its medical career with new jobs that could significantly disrupt healthcare and permanently shift pharmaceutical marketing practices. That might seem dramatic given Watson’s humble start as a game show contestant. But ever since it (I keep struggling to not say “he”) trounced the world’s best Jeopardy players, I’ve followed its rapid progress from Alex Trebek’s stage through medical education and now into gainful employment. With each step, I’ve become increasingly convinced that Watson and systems like it will drive or at least facilitate fundamental changes in healthcare—and healthcare marketing. So how might we respond?

From Jeopardy to oncology

For those who don’t know, it was reported this week that Watson will officially begin work helping doctors diagnose and treat patients, while helping insurers evaluate treatment coverage. This follows many months of Watson getting educated in medicine. For oncology, Watson was trained by the world’s best oncologists and has effectively consumed, as I understand it, every piece of useful data on the topic, including the latest research—with which it stays continuously up to date. It then uses the same approach it used on Jeopardy to apply that knowledge to diagnosis and treatment.

Physicians give Watson a case, just as Trebek gave it an answer, and Watson gives them diagnostic and treatment recommendations with varying probabilities of correctness. (Example: A 95% chance that, based on the information provided, a person has prostate cancer.) Physicians then choose to agree or disagree with Watson. But, as one oncologist noted during a pilot, it’s hard to disagree with a system that knows exponentially more than you, is trained by the world’s best physicians, and is completely up to date with the latest research.

And Watson isn’t the only system showing promise at improving diagnosis and treatment while reducing costs. Also this past week, Indiana University researchers reported on predictive modelling techniques that improve patient outcomes by 40% and reduce treatment costs by 50%.

Towards a new discipline: “Artificial Intelligence Optimization”

While the creators of these systems take pains to say they’re not displacing doctors, just augmenting them, I consider that political correctness rather than fact. With soaring costs, doctor shortages and challenges for doctors to keep pace with the increasing volume of research and data, it seems inevitable that a shift to artificially intelligent doctors will occur—especially since their “brain” can be distributed as software or made available via the cloud. (At the most controversial end of the spectrum, venture capitalist Vinod Khosla says machines will do 80% of what doctors currently do.)

Such a shift is already happening with web- and smartphone-based consumer tools. For example, Symcat provides patients with free big data-driven diagnoses, Medify provides patients with disease and treatment guidance based on evaluation of published research, and Treato, which I’ve written about previously, analyzes social media conversation to determine what real patients think of treatments.

If the shift towards machine-driven diagnostics and treatment, and away from physician-driven, continues, it could have a significant impact on pharmaceutical marketing. How do you influence an algorithm?

From my perspective, the common thread through these services is their reliance on data–structured and unstructured. Hence the focus of pharmaceutical marketing might need to shift increasingly towardsmaximizing the generation and digital distribution of data that improves appropriate diagnosis and treatment of patients who can benefit from an intervention. For example, investment might be warranted in:

  • Additional clinical trials that result in published data Watson and other systems can use for diagnostic, treatment and insurance recommendations
  • Encouraging patients to talk openly (in a compliant way, of course) in public forums about their positive experiences with a treatment, so social media aggregators pick up and analyze the posts
  • Data monitoring to identify and address prospective negative data that could adversely impact treatment usage

Of course, these are just some early thoughts. I imagine that as this trend hastens, we’ll develop dedicated disciplines to optimize data for artificial intelligence and analytics engines the way we currently optimize content for search engines. The good news is that, overall, this should improve the application of data to diagnosing and treating patients, while helping address ballooning healthcare costs. The challenge is that the path is uncertain; Watson is an amazing diagnostician, but it can’t predict the future.

At least not yet.


Simon's passion is developing scalable solutions to meaningful problems. His current focus is solving healthcare challenges with digital media. Previously, Simon founded Betterhumans, a digital media company focused on exploring the impact of emerging science and technology. Connect with him at simonsmith.ca, twitter.com/simonsmith and linkedin.com/in/simonsmith.
Print Email permalink (0) Comments (3276) Hits •  subscribe Share on facebook Stumble This submit to reddit submit to digg


COMMENTS


YOUR COMMENT (IEET's comment policy)

Login or Register to post a comment.

Next entry: Natural Born Cyborgs

Previous entry: Basic Income, a new human right

HOME | ABOUT | FELLOWS | STAFF | EVENTS | SUPPORT  | CONTACT US
SECURING THE FUTURE | LONGER HEALTHIER LIFE | RIGHTS OF THE PERSON | ENVISIONING THE FUTURE
CYBORG BUDDHA PROJECT | AFRICAN FUTURES PROJECT | JOURNAL OF EVOLUTION AND TECHNOLOGY

RSSIEET Blog | email list | newsletter |
The IEET is a 501(c)3 non-profit, tax-exempt organization registered in the State of Connecticut in the United States.

Contact: Executive Director, Dr. James J. Hughes,
56 Daleville School Rd., Willington CT 06279 USA 
Email: director @ ieet.org     phone: 860-297-2376